Immunophenotypic and genomic landscape of Richter transformation diffuse large B-cell lymphoma.

[1]  J. Hazle,et al.  Artificial intelligence-assisted mapping of proliferation centers allows the distinction of accelerated phase from large cell transformation in chronic lymphocytic leukemia , 2022, Modern Pathology.

[2]  I. Wistuba,et al.  Artificial intelligence strategy integrating morphologic and architectural biomarkers provides robust diagnostic accuracy for disease progression in chronic lymphocytic leukemia , 2021, The Journal of pathology.

[3]  J. McGowan-Jordan,et al.  Re: International System for Human Cytogenetic or Cytogenomic Nomenclature (ISCN): Some Thoughts, by T. Liehr , 2021, Cytogenetic and Genome Research.

[4]  R. Siebert,et al.  Clinical, biological, and molecular genetic features of Richter syndrome and prognostic significance: A study of the French Innovative Leukemia Organization , 2021, American journal of hematology.

[5]  Michael R. Green,et al.  BET proteolysis targeted chimera-based therapy of novel models of Richter Transformation-diffuse large B-cell lymphoma , 2021, Leukemia.

[6]  K. Patel,et al.  Lymphoid enhancer binding factor 1 (LEF1) expression is significantly higher in Hodgkin lymphoma associated with Richter syndrome relative to de novo classic Hodgkin lymphoma. , 2020, Annals of diagnostic pathology.

[7]  C. Niemann,et al.  Richter’s transformation in patients with chronic lymphocytic leukaemia: a Nationwide Epidemiological Study , 2020, Leukemia & lymphoma.

[8]  J. Khoury,et al.  Immunohistochemistry Innovations for Diagnosis and Tissue-Based Biomarker Detection , 2019, Current Hematologic Malignancy Reports.

[9]  S. Slager,et al.  Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center , 2019, Haematologica.

[10]  H. Knight,et al.  Herpes Simplex Necrotic Lymphadenitis Masquerading as Richter’s Transformation in Treatment-Naive Patients With Chronic Lymphocytic Leukemia , 2019, Journal of hematology.

[11]  U. Randen,et al.  Richter syndrome epidemiology in a large population based chronic lymphocytic leukemia cohort from Norway. , 2019, Cancer epidemiology.

[12]  B. Cheson,et al.  Descriptive analysis of genetic aberrations and cell of origin in Richter transformation , 2019, Leukemia & lymphoma.

[13]  P. Riedell,et al.  Double hit and double expressors in lymphoma: Definition and treatment , 2018, Cancer.

[14]  T. Shanafelt,et al.  PD-1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Large B-cell Richter Transformation (DLBCL-RT): A Characteristic Feature of DLBCL-RT and Potential Surrogate Marker for Clonal Relatedness , 2018, The American journal of surgical pathology.

[15]  D. Rossi,et al.  Biology and treatment of Richter syndrome. , 2018, Blood.

[16]  M. Horger,et al.  Diagnosis of Richter transformation in chronic lymphocytic leukemia: histology tips the scales , 2018, Annals of Hematology.

[17]  P. Jain,et al.  CLL progression after one cycle of FCR: Richter's transformation versus EBV‐associated lympho‐proliferation , 2017, American journal of hematology.

[18]  R. Broaddus,et al.  Validation of Immunohistochemical Assays for Integral Biomarkers in the NCI-MATCH EAY131 Clinical Trial , 2017, Clinical Cancer Research.

[19]  J. Friedberg.  How I treat double-hit lymphoma. , 2017, Blood.

[20]  L. Medeiros,et al.  Herpes simplex infection simulating Richter transformation: a series of four cases and review of the literature , 2017, Histopathology.

[21]  A. Schuh,et al.  Diagnostic dilemmas of high‐grade transformation (Richter's syndrome) of chronic lymphocytic leukaemia: results of the phase II National Cancer Research Institute CHOP‐OR clinical trial specialist haemato‐pathology central review , 2016, Histopathology.

[22]  L. Medeiros,et al.  Histologic transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma , 2016, American journal of hematology.

[23]  L. Medeiros,et al.  High-grade Transformation of Low-grade B-cell Lymphoma: Pathology and Molecular Pathogenesis , 2016, The American journal of surgical pathology.

[24]  L. Medeiros,et al.  Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patients , 2015, Journal of Hematology & Oncology.

[25]  M. Jarmuż-Szymczak,et al.  Cytogenetic and flow cytometry evaluation of Richter syndrome reveals MYC, CDKN2A, IGH alterations with loss of CD52, CD62L and increase of CD71 antigen expression as the most frequent recurrent abnormalities. , 2015, American journal of clinical pathology.

[26]  F. Stingo,et al.  BRAF kinase domain mutations are present in a subset of chronic myelomonocytic leukemia with wild‐type RAS , 2014, American journal of hematology.

[27]  Z. Estrov,et al.  Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia. , 2014, Blood.

[28]  Kai Fu,et al.  Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. , 2014, Blood.

[29]  Raul Rabadan,et al.  Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome , 2013, The Journal of experimental medicine.

[30]  W. Chan,et al.  Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome. , 2013, Blood.

[31]  T. Habermann,et al.  Diffuse large B‐cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients , 2013, British journal of haematology.

[32]  J. Downing,et al.  High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations. , 2012, Blood.

[33]  W. Choi,et al.  Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. , 2012, Blood.

[34]  K. Akashi,et al.  Self-renewing hematopoietic stem cell is the primary target in pathogenesis of human chronic lymphocytic leukemia. , 2011, Cancer cell.

[35]  G. Morgan,et al.  Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  S. Pileri,et al.  The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. , 2011, Blood.

[37]  H. Kantarjian,et al.  The great imitator: systemic nocardiosis mimicking Richter's transformation in relapsed chronic lymphocytic leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  Michael Hummel,et al.  Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL. , 2010, Blood.

[39]  E. Giné,et al.  Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia (“accelerated” chronic lymphocytic leukemia) with aggressive clinical behavior , 2010, Haematologica.

[40]  L. Ding,et al.  Aggressive Chronic Lymphocytic Leukemia with Elevated Genomic Complexity Is Associated with Multiple Gene Defects in the Response to DNA Double-Strand Breaks , 2010, Clinical Cancer Research.

[41]  Francesco Bertoni,et al.  Stereotyped B-Cell Receptor Is an Independent Risk Factor of Chronic Lymphocytic Leukemia Transformation to Richter Syndrome , 2009, Clinical Cancer Research.

[42]  M. Boccadoro,et al.  Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia , 2009, Leukemia.

[43]  D. Rossi,et al.  14q32 Translocations and risk of Richter transformation in chronic lymphocytic leukaemia , 2009, British journal of haematology.

[44]  Davide Rossi,et al.  Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome , 2008, British journal of haematology.

[45]  L. Staudt,et al.  Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. , 2006, Blood.

[46]  A. Rosenwald,et al.  IgVH Mutational Status and Clonality Analysis of Richter's Transformation: Diffuse Large B-cell Lymphoma and Hodgkin Lymphoma in Association With B-cell Chronic Lymphocytic Leukemia (B-CLL) Represent 2 Different Pathways of Disease Evolution , 2007, The American journal of surgical pathology.

[47]  L. Staudt,et al.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. , 2004, Blood.

[48]  L. Medeiros,et al.  Cytogenetic findings in blastoid mantle cell lymphoma. , 2003, Human pathology.

[49]  L. Staudt,et al.  The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.

[50]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.